Menu Search
Equities

Cytosorbents Corp

HQE1:DUS

Cytosorbents Corp

Actions
  • Price (EUR)0.878
  • Today's Change-0.01 / -1.13%
  • Shares traded--
  • 1 Year change-21.75%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 15:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cytosorbents Corp grew revenues 4.79% from 34.69m to 36.35m while net income improved from a loss of 32.81m to a smaller loss of 28.51m.
Gross margin62.71%
Net profit margin-49.47%
Operating margin-58.51%
Return on assets-39.15%
Return on equity-118.50%
Return on investment-49.80%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Cytosorbents Corp fell by 8.22m. Cash Flow from Financing totalled 14.47m or 39.82% of revenues. In addition the company used 21.66m for operations while cash used for investing totalled 936.24k.
Cash flow per share-0.3236
Price/Cash flow per share--
Book value per share0.2385
Tangible book value per share0.2385
More ▼

Balance sheet in USDView more

Cytosorbents Corp has a Debt to Total Capital ratio of 51.51%, a higher figure than the previous year's 22.68%.
Current ratio1.97
Quick ratio1.58
Total debt/total equity1.06
Total debt/total capital0.515
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.